The US clinical trial management systems (CTMS) market is poised for steady growth through 2008, achieving a five-year compound annual growth rate (CAGR) of nearly 13%, a new research study from Life Science Insights reveals. Analysts expect the market for CTMS software licenses to grow during the same forecast period, from $193 mln to $360 mln. While component technologies, such as EDC, play a major role in these markets, systems designed to manage multiple aspects of clinical trial management will drive adoption of CTMS among pharmaceutical and biotechnology companies.
Security
MuleSoft strategy sets up an example for the whole industry to follow
Join Discussion